Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441566 in healthy Japanese males
NCT05858788Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balinatunfib in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration and 1 more. Started May 2023; status: completed.
02
Drugs
balinatunfib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05858788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858788.